Subcutaneous delivery of polymer conjugates of therapeutics agents
AssigneeSerina Therapeutics, Inc.
InventorsRandall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
Life of this patent
Estimating the term…
Abstract
The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
Claims22
A method for treating a disease or condition related to dopamine insufficiency in the peripheral or central nervous system in a subject, the method comprising the step of administering to the subject a poly(oxazoline) polymer conjugate comprising a water soluble poly(oxazoline) polymer and an agent, wherein the agent is a dopamine agonist, an adenosine A2A receptor antagonist, an anticholinergic, a monamine oxidase-B inhibitor or a catechol—O—methyl transferase inhibitor, and wherein a release profile of the agent is selectable based on the selection of the poly(oxazoline) polymer conjugate, the poly(oxazoline) polymer conjugate having the structure:
- wherein
- L is
- R3 forms a linkage with the poly(oxazoline) polymer;
- R4 is —CH2—C(O)—O—, —CH(CH3)—C(O)—O—, —CH2—CH2—C(O)—O—, —CH2—CH2—CH2—C(O)—O—, —CH2—O—C(O)—, —CH2(CH3)—O—C(O)—, —CH2—CH2—O—C(O)—or —CH2—O—CH2—O—C(O)—;
- R is an initiating group;
- R1 is a non-reactive group;
- A is the agent;
- a is ran which indicates a random copolymer or block which indicates a block copolymer;
- o is from 1-50;
- m is from 1-1000;
- and
- T is a terminating group, wherein the release profile is dependent on the selection of R4.
A method for treating a disease or condition related to dopamine insufficiency in the peripheral or central nervous system in a subject, the method comprising the step of administering to the subject a poly(oxazoline) polymer conjugate comprising a water soluble poly(oxazoline) polymer and a dopamine agonist, wherein a release profile of the dopamine agonist is selectable based on the selection of the poly(oxazoline) polymer conjugate, the poly(oxazoline) polymer conjugate having the structure:
- wherein
- L is R3 forms a linkage with the poly(oxazoline) polymer;
- R4 is —CH2—C(O)—O—, —CH(CH3)—C(O)—O—, —CH2—CH2—C(O)—O—, —CH2—CH2—CH2—C(O)—O—, —CH2—O—C(O)—, —CH2(CH3)—O—C(O)—, —CH2—CH2—O—C(O)—or —CH2—CH2—CH2—O—C(O)—;
- R is an initiating group;
- R1 is a non-reactive group;
- A is the dopamine agonist;
- a is ran which indicates a random copolymer or block which indicates a block copolymer;
- o is from 1-50;
- m is from 1-1000;
- and
- T is a terminating group, wherein the release profile is dependent on the selection of R4.
A method for treating a disease or condition related tO dopamine insufficiency in the peripheral or central nervous system in a subject, the method comprising the step of subcutaneously administering to the subject a therapeutically effective amount of a poly(oxazoline) polymer conjugate comprising a water soluble poly(oxazoline) polymer and an agent, wherein the agent is a dopamine agonist, an adenosine A2A receptor antagonist, an anticholinergic, a monamine oxidase-B inhibitor or a catechol-O-methyl transferase inhibitor, and wherein a release profile of the agent is selectable based on the selection of the poly(oxazoline) polymer conjugate, the poly(oxazoline) polymer conjugate having the structure:
- wherein
- L is
- R3 forms a linkage with the poly(oxazoline) polymer;
- R4 is —CH2—C(O)—O—, —CH(CH3)—C(O)—O—, —CH2—CH2—C(O)—O—, —CH2—CH2—CH2—C(O)—O—, —CH2—O—C(O)—, —CH2(CH3)—O—C(O)—, —CH2—CH2—O—C(O)—or —CH2—CH2—CH2—O—C(O)—;
- R is an initiating group;
- R1 is a non-reactive group;
- A is the agent;
- a is ran which indicates a random copolymer or block which indicates a block copolymer;
- o is from 1-50;
- m is from 1-1000;
- and
- T is a terminating group, wherein the release profile is dependent on the selection of R4.
Dependencies are inferred from the claim text.